Search - tctmd.com

Displaying 621 - 640 of 762

Sort: Relevancy | Date

News Daily News

It’s DESTINY: DES Superior to BMS for Below-the-Knee Lesions

Jason Kahn

March 06, 2012

News Daily News

Study Urges Higher Cutoff for Troponin Elevation in Diagnosing MI

Caitlin E. Cox

March 05, 2012

News Daily News

PEPCAD-DES: Paclitaxel-Coated Balloon Bests Plain Balloon for DES Restenosis

March 05, 2012

News Daily News

Meta-Analysis: Mixed Results Seen with First-Gen DES in STEMI Patients

March 05, 2012

News Daily News

Angiotensin Blocker Preserves Endothelial Function Better Than Calcium Antagonist

Jason Kahn

March 05, 2012

News Industry News

Boston Scientific Receives Industry's First FDA Approval for Drug-Eluting Coronary Stent Use in Heart Attack Patients

February 21, 2012

News Daily News

Resolute Integrity: New Zotarolimus-Eluting Stent Gains FDA Approval

L.A. McKeown

February 20, 2012

News Daily News

Complications of In-Stent Restenosis High, Traditional Risk Factors Absent

Yael L. Maxwell

February 15, 2012

News Industry News

Increased reimbursement of Self-Expanding drug-eluting stents in Germany now for all indications

February 07, 2012

News Daily News

NEXT Up: Polymer-Free SES Angiographically Superior to Taxus

January 24, 2012

News Daily News

Stent Thrombosis, TLR Persist at Low Levels out to 5 Years with First-Gen DES

Jason Kahn

January 08, 2012

News Daily News

SCAAR: Second-Generation DES Improve Hard Outcomes

Yael L. Maxwell

January 08, 2012

News Daily News

DES Show Better Outcomes vs. BMS in Elderly, Though Use Declining

Leah Lawrence

January 05, 2012

News Industry News

Abbott Initiates Clinical Trial To Study Drug Eluting Bioresorbable Therapy For Treatment Of Peripheral Artery Disease

December 31, 2011

News Industry News

Use of OrbusNeich’s Genous™ Stent in a Coronary Bifurcation Setting Is Feasible and Safe, with No Incidence of Late Stent Thrombosis and a Very Low Rate of Repeated Revascularization

December 19, 2011

News Daily News

FFR-Guidance Demonstrates Benefits in Patients with Unstable Angina, NSTEMI

L.A. McKeown

December 08, 2011

News Daily News

Elevated CRP—But Not High Platelet Reactivity—Predictive After DES

December 04, 2011

News Conference News

ROTAXUS: Rotablation Does Not Improve Stenting Results in Calcified Lesions

Yael L. Maxwell

November 30, 2011

News Daily News

Some New-Generation Stents Prone to Longitudinal Distortion

November 29, 2011

News Conference News

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

L.A. McKeown

November 28, 2011

Advertisement

It’s DESTINY: DES Superior to BMS for Below-the-Knee Lesions

Study Urges Higher Cutoff for Troponin Elevation in Diagnosing MI

PEPCAD-DES: Paclitaxel-Coated Balloon Bests Plain Balloon for DES Restenosis

Meta-Analysis: Mixed Results Seen with First-Gen DES in STEMI Patients

Angiotensin Blocker Preserves Endothelial Function Better Than Calcium Antagonist

Boston Scientific Receives Industry's First FDA Approval for Drug-Eluting Coronary Stent Use in Heart Attack Patients

Resolute Integrity: New Zotarolimus-Eluting Stent Gains FDA Approval

Complications of In-Stent Restenosis High, Traditional Risk Factors Absent

Increased reimbursement of Self-Expanding drug-eluting stents in Germany now for all indications

NEXT Up: Polymer-Free SES Angiographically Superior to Taxus

Stent Thrombosis, TLR Persist at Low Levels out to 5 Years with First-Gen DES

SCAAR: Second-Generation DES Improve Hard Outcomes

DES Show Better Outcomes vs. BMS in Elderly, Though Use Declining

Abbott Initiates Clinical Trial To Study Drug Eluting Bioresorbable Therapy For Treatment Of Peripheral Artery Disease

Use of OrbusNeich’s Genous™ Stent in a Coronary Bifurcation Setting Is Feasible and Safe, with No Incidence of Late Stent Thrombosis and a Very Low Rate of Repeated Revascularization

FFR-Guidance Demonstrates Benefits in Patients with Unstable Angina, NSTEMI

Elevated CRP—But Not High Platelet Reactivity—Predictive After DES

ROTAXUS: Rotablation Does Not Improve Stenting Results in Calcified Lesions

Some New-Generation Stents Prone to Longitudinal Distortion

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content